SCHEMBL2930091

SCHEMBL2930091

O=C1CCC(c2ccc3c(c2)CC(=O)N3)=NN1

nearest known ligand 0.63

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
PDE3B Q13370 11/20 0.63
PDE3A Q14432 11/20 0.63
PDE4A P27815 7/20 0.60
PDE4B Q07343 7/20 0.60
PDE4C Q08493 7/20 0.60
PDE4D Q08499 7/20 0.60
SMN1; SMN2 Q16637 1/20 0.51
CYP1A2 P05177 1/20 0.51
CYP11B1 P15538 1/20 0.51
CYP11B2 P19099 1/20 0.51
GRIA1 P42261 2/20 0.50
CACNG8 Q8WXS5 2/20 0.50
PGR P06401 1/20 0.50
AHR P35869 1/20 0.47
KIF11 P52732 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10595977 0.90 PDE3B (0.64) PDE3BPDE3APDE4APDE4BPDE4C
SCHEMBL7417981 0.82 PDE3B (0.57) PDE3BPDE3APDE4APDE4BPDE4C
Prinoxodan SCHEMBL122042 0.80 PDE3B (0.55) PDE3BPDE3APDE4APDE4BPDE4C
SCHEMBL10835125 0.80 PDE3B (0.59) PDE3BPDE3APDE4APDE4BPDE4C
SCHEMBL10744506 0.79 PDE3B (0.54) PDE3BPDE3APDE4APDE4BPDE4C
SCHEMBL7483850 0.78 PDE3B (0.70) PDE3BPDE3APDE4APDE4BPDE4C
SCHEMBL10596133 0.77 PDE3B (0.61) PDE3BPDE3APDE4APDE4BPDE4C
SCHEMBL10353452 0.77 SMN1; SMN2 (0.81) PDE3BPDE3APDE4APDE4BPDE4C
SCHEMBL7342078 0.76 PDE3B (0.53) PDE3BPDE3APDE4APDE4BPDE4C
SCHEMBL9590230 0.76 PDE3B (0.59) PDE3BPDE3APDE4APDE4BPDE4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0155798-B1 PYRIDAZONE INOTROPIC AGENTS ELI LILLY AND COMPANY (US) 1989-02-08 EP claimed
US-4591591-A FOR TREATING HEART FAILURE ELI LILLY AND COMPANY (US) 1986-05-27 US claimed
EP-0155798-A1 Pyridazone inotropic agents ELI LILLY AND COMPANY (US) 1985-09-25 EP claimed
US-20260077139-A1 SPACER DEVICE WITH FLOW RATE SPIROMETER AEROVU TECHNOLOGIES, INC. (US) 2026-03-19 US disclosed
US-12514993-B2 Spacer device with flow rate spirometer AEROVU TECHNOLOGIES, INC. (US) 2026-01-06 US disclosed
US-20250339374-A1 BONDED MICROPARTICULATES PREPARATION AND APPLICATIONS THEREOF VENKOR CORP (US) 2025-11-06 US disclosed
WO-2023234935-A1 BONDED MICROPARTICULATES PREPARATION AND APPLICATIONS THEREOF VENKOR CORPORATION (US) 2023-12-07 WO disclosed
US-11590084-B2 Microcapsules for controlled delivery of an active pharmaceutical ingredient BIELSKI ROMAN (US) 2023-02-28 US disclosed
EP-3194033-B1 SPACER DEVICE WITH FLOW RATE SPIROMETER AEROVU TECH INC (US) 2022-05-04 EP disclosed
US-20190125687-A1 Microcapsules for Controlled Delivery of an Active Pharmaceutical Ingredient BIELSKI ROMAN (US) 2019-05-02 US disclosed
US-9919116-B2 Inhaler VECTURA DELIVERY DEVICES LIMITED (GB) 2018-03-20 US disclosed
EP-0155798-B1 PYRIDAZONE INOTROPIC AGENTS ELI LILLY AND COMPANY (US) 1989-02-08 EP disclosed
US-4647564-A PYRIDAZINONE DERIVATIVES ELI LILLY AND COMPANY (US) 1987-03-03 US disclosed
US-4591591-A FOR TREATING HEART FAILURE ELI LILLY AND COMPANY (US) 1986-05-27 US disclosed
EP-0161918-A2 Indoline and 2-indolinone derivatives ELI LILLY AND COMPANY (US) 1985-11-21 EP disclosed
EP-0155798-A1 Pyridazone inotropic agents ELI LILLY AND COMPANY (US) 1985-09-25 EP disclosed
US-4474785-A HYPOTENSIVE AGENTS, ANTICOAGULANTS BASF AKTIENGESELLSCHAFT (DE) 1984-10-02 US disclosed
EP-0068310-B1 2-ARYL-3,4-DIAZA-BICYCLO(4.N.0)ALKEN-(2)-ONES-(5), PROCESS FOR THEIR PREPARATION, AND MEDICINES CONTAINING THESE COMPOUNDS BASF Aktiengesellschaft (DE) 1984-08-08 EP disclosed
EP-0068310-A1 2-Aryl-3,4-diaza-bicyclo(4.n.0)alken-(2)-ones-(5), process for their preparation, and medicines containing these compounds BASF Aktiengesellschaft (DE) 1983-01-05 EP disclosed
US-4258185-A HYPOTENSIVE, ANTITHROMBOTIC AGENTS YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 1981-03-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190125687-A1 Microcapsules for Controlled Delivery of an Active Pharmaceutical Ingredient PUF60, SRM, SMS PDE3B 2656/4885PDE3A 2277/4885PDE4A 3265/4885
US-20260077139-A1 SPACER DEVICE WITH FLOW RATE SPIROMETER TMCO1, CFTR, CYSLTR2 PDE3B 1302/4885PDE3A 878/4885PDE4A 1992/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.